Top

International Journal of Clinical Oncology

Published in:

01-04-2016 | Original Article

Human collagen XV is a prominent histopathological component of sinusoidal capillarization in hepatocellular carcinogenesis

Authors: Kouji Kimura, Masaru Nakayama, Ichiro Naito, Takaaki Komiyama, Kouichi Ichimura, Hiroaki Asano, Kazunori Tsukuda, Aiji Ohtsuka, Toshitaka Oohashi, Shinichiro Miyoshi, Yoshifumi Ninomiya

Published in: International Journal of Clinical Oncology | Issue 2/2016

Abstract

Background

Increased expression of collagen XV has been reported in hepatocellular carcinogenesis in mice. The aim of this study was to confirm the previous murine findings in human hepatocellular carcinoma (HCC) specimens, along with the histopathological distribution of collagen XV in tumoral tissues.

Methods

Sixty-three primary HCC specimens were examined. Immunostaining of collagen XV and quantitative reverse transcriptional PCR of COL15A1, which encodes collagen XV, were performed.

Results

Positive staining of collagen XV was observed in all tumoral regions, regardless of differentiation level or pathological type of HCC, along the sinusoid-like endothelium, whereas collagen XV was not expressed in any non-tumoral region. The intensity score of collagen XV immunostaining and the mRNA value of COL15A1 were significantly correlated. COL15A1 expression in tumors was 3.24-fold higher than in non-tumoral regions. Multivariate analysis showed that COL15A1 expression was significantly higher in the absence of hepatitis virus and moderately differentiated HCC.

Conclusions

COL15A1 mRNA was up-regulated in HCC and collagen XV was expressed along the sinusoid-like endothelium of HCC but not in non-tumoral regions, which implies that collagen XV contributes to the capillarization of HCC.

Venook AP, Papandreou C, Furuse J et al (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15(Suppl 4):5–13CrossRefPubMed

El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576CrossRefPubMed

Simonetti RG, Cammà C, Fiorello F et al (1991) Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36:962–972CrossRefPubMed

De Mitri MS, Poussin K, Baccarini P et al (1995) HCV-associated liver cancer without cirrhosis. Lancet 345:413–415CrossRefPubMed

Moriya K, Fujie H, Shintani Y et al (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065–1067CrossRefPubMed

Saunders D, Seidel D, Allison M et al (2010) Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther 31:1051–1063PubMed

Adami HO, Chow WH, Nyrén O et al (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472–1477CrossRefPubMed

Hassan MM, Curley SA, Li D et al (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938–1946CrossRefPubMedPubMedCentral

Hashimoto E, Yatsuji S, Tobari M et al (2009) Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 44(Suppl 19):89–95CrossRefPubMed

10.

Ascha MS, Hanouneh IA, Lopez R et al (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972–1978CrossRefPubMed

11.

Hirohashi S, Ishak KG, Kojiro M et al (2000) Hepatocellular carcinoma. WHO classification of tumors. In: Hamilton SR, Aaltonen LA (eds) Pathology and genetics of tumors of the digestive system. IARC Press, Lyon, pp 159–172

12.

Sakamoto M, Hirohashi S, Shimosato Y (1991) Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 22:172–178CrossRefPubMed

13.

International Consensus Group for Hepatocellular Neoplasia The International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664CrossRef

14.

Wisse E, De Zanger RB, Charels K et al (1985) The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 5:683–692CrossRefPubMed

15.

Brunt EM, Gouw ASH, Hubscher SG et al (2014) Pathology of the liver sinusoids. Histopathology 64:907–920CrossRefPubMed

16.

Schaffner F, Poper H (1963) Capillarization of hepatic sinusoids in man. Gastroenterology 44:239–242PubMed

17.

Isomura T, Nakashima T (1980) Ultrastructure of human hepatocellular carcinoma. Acta Pathol Jpn 30:713–726PubMed

18.

Martinez-Hernandez A (1985) The hepatic extracellular matrix. II. Electron immunohistochemical studies in rats with CCl4-induced cirrhosis. Lab Invest 53:166–186PubMed

19.

Ichida T, Hata K, Yamada S et al (1990) Subcellular abnormalities of liver sinusoidal lesions in human hepatocellular carcinoma. J Submicrosc Cytol Pathol 22:221–229PubMed

20.

Kin M, Torimura T, Ueno T et al (1994) Sinusoidal capillarization in small hepatocellular carcinoma. Pathol Int 44:771–778CrossRefPubMed

21.

Yamamoto T, Kaneda K, Hirohashi K et al (1996) Sinusoidal capillarization and arterial blood supply continuously proceed with the advance of the stages of hepatocarcinogenesis in the rat. Jpn J Cancer Res 87:442–450CrossRefPubMed

22.

Lai KK, Shang S, Lohia N et al (2011) Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 7:e1002147CrossRefPubMedPubMedCentral

23.

Lien HC, Lee YH, Jeng YM et al (2014) Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology 65:328–339CrossRefPubMed

24.

Hahn E, Wick G, Pencev D et al (1980) Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 21:63–71CrossRefPubMedPubMedCentral

25.

Schuppan D (1990) Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 10:1–10CrossRefPubMed

26.

Myers JC, Dion AS, Abraham V et al (1996) Type XV collagen exhibits a widespread distribution in human tissues but a distinct localization in basement membrane zones. Cell Tissue Res 286:493–505CrossRefPubMed

27.

Hägg PM, Hägg PO, Peltonen S et al (1997) Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol 150:2075–2086PubMedPubMedCentral

28.

Tomono Y, Naito I, Ando K et al (2002) Epitope-defined monoclonal antibodies against multiplexin collagens demonstrate that type XV and XVIII collagens are expressed in specialized basement membranes. Cell Struct Funct 27:9–20CrossRefPubMed

29.

Mutolo MJ, Morris KJ, Leir SH et al (2012) Tumor suppression by collagen XV is independent of the restin domain. Matrix Biol 31:285–289CrossRefPubMedPubMedCentral

30.

Amenta PS, Briggs K, Xu K et al (2000) Type XV collagen in human colonic adenocarcinomas has a different distribution than other basement membrane zone proteins. Hum Pathol 31:359–366CrossRefPubMed

31.

Amenta PS, Hadad S, Lee MT et al (2003) Loss of types XV and XIX collagen precedes basement membrane invasion in ductal carcinoma of the female breast. J Pathol 199:298–308CrossRefPubMed

32.

Tanaka S, Arii S (2010) Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol 15:235–241CrossRefPubMed

33.

Zhu AX, Duda DG, Sahani DV et al (2011) HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 8:292–301CrossRefPubMedPubMedCentral

34.

Finn RS, Zhu AX (2009) Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 9:503–509CrossRefPubMed

Title: Human collagen XV is a prominent histopathological component of sinusoidal capillarization in hepatocellular carcinogenesis
Authors: Kouji Kimura
Masaru Nakayama
Ichiro Naito
Takaaki Komiyama
Kouichi Ichimura
Hiroaki Asano
Kazunori Tsukuda
Aiji Ohtsuka
Toshitaka Oohashi
Shinichiro Miyoshi
Yoshifumi Ninomiya
Publication date: 01-04-2016
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0888-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2016

Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy

Development and future directions of antiangiogenic therapy in hepatocellular carcinoma

Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer

Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy

The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients

Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer